Faecalibacterium prausnitzii Ameliorates DSS-Induced Colitis via Modulating Bile Acid Metabolism and Regulating FXR Signaling
- 5 July 2025
- journal article
- research article
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 70 (10) , 3323-3339
Abstract
Background Ulcerative colitis (UC) is a chronic relapsing inflammatory bowel disease with a globally increasing incidence. Faecalibacterium prausnitzii (F. prausnitzii) is known for its anti-inflammatory and immunomodulatory properties. However, the mechanisms by which gut microbiota and bile acid metabolism contribute to the therapeutic effects of F. prausnitzii in colitis remain unclear. Aims This study aims to investigate the effects of F. prausnitzii on colitis and elucidate its potential mechanism through modulation of gut microbiota and bile acid metabolism. Methods Mice were treated with dextran sulfate sodium (DSS), followed by administration of F. prausnitzii and its supernatant. Colitis symptoms, inflammatory responses, and intestinal barrier integrity were then evaluated. 16S rRNA sequencing and targeted bile acid metabolomics analysis were performed. Results F. prausnitzii and its supernatant reshaped dysbiotic gut microbiota in DSS-induced colitis mouse models, increasing the ratio of unconjugated to conjugated bile acids and secondary to primary bile acids, thereby activating the farnesoid X receptor (FXR) signaling pathway. Experiments in FXR−/− mice confirmed that FXR is a critical target for the protective effects of F. prausnitzii, promoting intestinal mucosal repair and inhibiting NLRP3 inflammasome activation, which in turn alleviates colitis. Additionally, the differential bile acid isoLCA, enriched by F. prausnitzii and its supernatant, effectively suppressed inflammation and enhanced intestinal barrier function. Conclusion This study demonstrates that F. prausnitzii alleviates colitis by modulating bile acid composition and regulating FXR signaling, suggesting that targeting the microbiota–bile acid–FXR pathway may represent a promising therapeutic strategy for inflammatory bowel disease.Keywords
Funding Information
- National Natural Science Foundation of China (82170551)
This publication has 69 references indexed in Scilit:
- Microbial-derived bile acid reverses inflammation in IBD via GPBAR1 agonism and RORγt inverse agonismBiomedicine & Pharmacotherapy, 2024
- Genus unclassified_Muribaculaceae and microbiota-derived butyrate and indole-3-propionic acid are involved in benzene-induced hematopoietic injury in miceChemosphere, 2022
- Farnesoid X receptor (FXR): Structures and ligandsComputational and Structural Biotechnology Journal, 2021
- Bile Acid Signaling in Inflammatory Bowel DiseasesDigestive Diseases and Sciences, 2020
- The microbiome in inflammatory bowel diseases: from pathogenesis to therapyProtein & Cell, 2020
- Dysbiosis-Induced Secondary Bile Acid Deficiency Promotes Intestinal InflammationCell Host & Microbe, 2020
- Splenic dendritic cell involvement in FXR-mediated amelioration of DSS colitisBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2016
- Bile acid nuclear receptor FXR and digestive system diseasesActa Pharmaceutica Sinica B, 2015
- The bile acid TGR5 membrane receptor: From basic research to clinical applicationDigestive and Liver Disease, 2014
- Faecalibacterium prausnitzii upregulates regulatory T cells and anti-inflammatory cytokines in treating TNBS-induced colitisJournal of Crohn's and Colitis, 2013